The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation a...

Full description

Bibliographic Details
Main Authors: Leila Atmowihardjo, Job R. Schippers, Imke H. Bartelink, Pierre M. Bet, Nienke van Rein, Keith Purdy, David Cavalla, Valérie Comberiati, Andrew McElroy, Sue D. Snape, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Trials
Subjects:
COVID-19
Randomized controlled trial
Protocol
ARDS
Imatinib
Extravascular lung water
Online Access:https://doi.org/10.1186/s13063-022-06055-9

Internet

https://doi.org/10.1186/s13063-022-06055-9

Similar Items